WHO

World Health Organization Executive Board to create new consultative expert working group on R&D Financing

Today the WHO is expected to take up the Report by the Secretariat on "the Establishment of a consultative expert working group on research and development: financing and coordination." (link here).

Why does Bill Gates oppose discussions of a medical R&D treaty at the World Health Organization?

1. General opposition to multilateral institutions having a role in setting global norms for medical R&D
9% (22 votes)
2. Sees treaty as threat to tough global norms for intellectual property rights
29% (71 votes)
3. Thinks governments already spend too much on research to develop new medicines
2% (6 votes)
4. Both 1 & 2
47% (116 votes)
5. None of the above
12% (30 votes)
Total votes: 245

European Commission October 5, 1998 note memorandum on the WHO Revised Drug Strategy negotiation

 

European Commission (DG 1) note on the WHO's Revised Drug Stategy

 


EUROPEAN COMMISSION

DIRECTORATE GENERAL 1
EXTERNAL RELATIONS: COMMERCIAL POLICY AND RELATIONS WITH NORTH AMERICA. THE
FAR EAST, AUSTRALIA AND NEW ZEALAND

 

Directorate D -Sectoral trade questions, market access
New technologies, Intellectual property, public procurement


Brussels, 5 October 1998
1/D/3/BW D (98)

 

1998/1999 debate over 52.19, the WHO Revised Drug Strategy

The following are selected documents from the 1998 to 1999 WHO debate of the revised drug strategy.

WHA 52.19, the Revised Drug Strategy

A pdf copy of the resolution is attached to this page.


THE FIFTY-SECOND WORLD HEALTH ASSEMBLY
WHA52.19

Agenda Item 13
May 24, 1999


Revised Drug Strategy

The Fifty-second World Health Assembly,

Recalling resolution WHA39.27, WHA41.16, WHA43.20, WHA45.27, WHA47.12, WHA47.13, WHA47.16, WHA47.17, and WHA49.14;

Having considered the report of the Director-General on the revised drug strategy[1];

May 27, 1998 Department of State cable: REVISED DRUG STRATEGY AT W.H.O.: ATMOSPHERICS OF THE DEBATE, AND RECOMMENDED PLAN OF ACTION

CONFIDENTIAL RELEASED IN FULL
CONFIDENTIAL PTQ1906

PAGE 01 GENEVA 03470 01 OF 09 271621Z ACTION 10-00

425261 271705Z /38 O 271615Z MAY 98

FM USMISSION GENEVA
TO SECSTATE WASHDC IMMEDIATE 6208 INFO IO COLLECTIVE AMEMBASSY LONDON
AMEMBASSY BRASILIA
AMEMBASSY BUENOS AIRES AMEMBASSY PRETORIA AMEMBASSY HARARE
AMEMBASSY LILONGWE AMEMBASSY LUSAKA
AMEMBASSY WINDHOEK AMEMBASSY BERN
AMEMBASSY CANBERRA
AMEMBASSY STOCKHOLM AMEMBASSY TOKYO AMEMBASSY OSLO
AMEMBASSY BRUSSELS AMEMBASSY BONN
AMEMBASSY OTTAWA AMEMBASSY CAIRO CDC ATLANTA

Anne Marie Worning appointed as new acting head of WHO's team on public health, innovation and intellectual property

On 4 June 2010, Dr. Margaret Chan (Director General, World Health Organization) announced Dr. Anne Marie Worning as 'acting Director, Public Health, Innovation and Intellectual Property (PHI)'. According to the WHO website,

Dr Anne Marie Worning, a Danish national, is the Executive Director of the Director-General's Office since April 2009.

Global Health Progress/IFPMA fete African health ministers in Geneva on public private partnerships

On 19 May 2010, Global Health Progress (GHP) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) hosted a luncheon at the Vieux Bois in Geneva on the margins of the 63rd World Health Assembly for a targeted audience of over 90 persons including Ministers of Health, Ambassadors and senior officials from the Africa.

SAVE THE DATE: 19 May 2010-Moving beyond the EWG: Charting a new path for WHO to promote innovation AND access to medicines

Moving beyond the EWG: Charting a new path for WHO to promote innovation AND access to medicines

Non-governmental organization perspectives on de-linkage, prizes and the R+D Treaty

Date: Wednesday, 19 May 2010
Location: Salle XXV, Palais des Nations
Time: 13:00 to 14:30

I+A: Innovation+Access

Syndicate content